banner
PKD inhibitor CRT-0066101, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ198

PKD inhibitor CRT-0066101, Purity ≥98%

Inquiry

Synonym: 1883545-60-5; CRT0066101; CRT0066101 Dihydrochloride; (R)-2-(4-((2-Aminobutyl)amino)pyrimidin-2-yl)-4-(1-methyl-1H-pyrazol-4-yl)phenol dihydrochloride; PKD inhibitor

  • CAS Number: 1883545-60-5
  • Compound CID: 136664697
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
Datasheet
MSDS
MSDS
Properties
Description
CRT-0066101, soluble in warmed DMSO, water and warmed ethanol, typically functions by binding to the ATP-binding site of the kinase domain, thereby preventing the phosphorylation and activation of downstream substrates.
Molecular Weight
411.33
Molecular Formula
C18H22N6O.2HCl
Form
Lyophilized powder
Purity
≥98%
Solubility
Warmed DMSO: 25 mg/mL (60.77 mM); Water: 80 mg/mL (194.49 mM); Warmed ethanol: 2 mg/mL
Identity
Confirmed by NMR/HPLC/MS.
Applications
CRT-0066101 can be used to study the inhibition of protein kinase D (PKD) signaling pathways.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links
(AI-CD BioGlyco)
Analysis of Sialic Acid in Human Milk
(CD BioGlyco)
Biological Evaluation Service
(CD BioGlyco)
Glyconanotechnology-based Biosensor Development
PRODUCTS
Featured Products
Nucleic Acid Drug Delivery Products
GalNAc-L96 intermediate, T1 (Cat#: X24-11-YM010) GalNAc-L96 intermediate, T2 (Cat#: X24-11-YM011) GalNAc-L96 intermediate, T3 (Cat#: X24-11-YM012) GalNAc-L96 intermediate, T4-Amine (Cat#: X24-11-YM014) Tri-GalNAc(OAc)3 Cbz (Cat#: X24-11-YM015) Tri-GalNAc(OAc)3 (Cat#: X24-11-YM016) Tri-GalNAc(OAc)3 TFA (Cat#: X24-11-YM017) GalNAc-L96-OH (Cat#: X24-11-YM018) GalNAc-L96-TEA (Cat#: X24-11-YM019)
Hots Products
N-Glycan
Neu5Gcα(2-6)N-Glycan (Cat#: X23-03-YW036) A2G2 N-Glycan (Cat#: X23-03-YW037) A2G2S2 N-Glycan (Cat#: X23-03-YW038) A2 N-Glycan (Cat#: X23-03-YW039) A2[6]G1 N-Glycan (Cat#: X23-03-YW040) M3 N-Glycan (Cat#: X23-03-YW041) A2[3]G2S1 N-Glycan (Cat#: X23-03-YW042)
O-Glycan
Core 2 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW178) Core 2 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW179) Core 3 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW180) Core 3 O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW181) Core 4 O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW182) T antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW192) T antigen O-glycan, Thr-Fmoc linked (Cat#: X23-10-YW193) Tn antigen O-glycan, Ser-Fmoc linked (Cat#: X23-10-YW194)
Blood Group and Lewis Antigen
Blood group A trisaccharide (Cat#: XCO0060Q) Blood group B trisaccharide (Cat#: XCO0068Q) Blood group H disaccharide (Cat#: XCO0074Q) Lewis A trisaccharide (Cat#: XCO0079Q) 3'-Sulfated lewis A (Cat#: XCO0080Q) Lewis B tetrasaccharide (Cat#: XCO0083Q) Lewis X trisaccharide (Cat#: XCO0085Q) Lewis Y tetrasaccharide (Cat#: XCO0088Q)
Human Milk Oligosaccharides (HMOs)
Lacto-N-biose (Cat#: XCO0089Q) 2'-Fucosyllactose (Cat#: XCO0091Q) 3-Fucosyllactose (Cat#: XCO0092Q) Lactodifucotetraose (Cat#: XCO0093Q) Lacto-N-triose I (Cat#: XCO0094Q) 3'-Sialyllactose sodium salt (Cat#: XCO0096Q) 6'-Sialyllactose sodium salt (Cat#: XCO0098Q) 3'-Sialyl-3-fucosyllactose (Cat#: XCO0100Q)
Glycosaminoglycans
Heparin amine, MW 27 kDa (Cat#: X22-09-ZQ478) FITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ480) TRITC-heparin, MW 27 kDa (Cat#: X22-09-ZQ481) Biotin-heparin-FITC, MW 18 kDa (Cat#: X22-09-ZQ482) Chondroitin sulfate (dp4) (Cat#: X22-11-ZQ598) Dermatan sulfate (dp12) (Cat#: X22-11-ZQ611) Heparin disaccharide I-A (Cat#: X22-11-ZQ662) Chondroitine sulfate (Cat#: X23-04-XQ1118)
Carbohydrate Conjugates
GalNAcβ(1-4)GlcNAcβ-Sp3-Biotin (Cat#: X22-12-ZQ005) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-Biotin (Cat#: X22-12-ZQ006) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA-FITC (Cat#: X22-12-ZQ007) GalNAcβ(1-4)GlcNAcβ-Sp3-PAA (Cat#: X22-12-ZQ008) Glcβ(1-4)GalNAcα-Sp3-Biotin (Cat#: X22-12-ZQ037) Glcβ(1-4)GalNAcα-Sp3-PAA-Biotin (Cat#: X22-12-ZQ038) Glcβ(1-4)GalNAcα-Sp3-PAA-FITC (Cat#: X22-12-ZQ039) Glcβ(1-4)GalNAcα-Sp3-PAA (Cat#: X22-12-ZQ040)
Glycolipids
GlcCer (d18:1/8:0) (Cat#: X23-11-ZQ101) GalCer (d18:1/16:0) (Cat#: X23-11-ZQ112) LacCer (d18:1/8:0) (Cat#: X23-11-ZQ118) Lc3Cer (d18:1/8:0) (Cat#: X23-11-ZQ131) Lc4Cer (d18:1/12:0) (Cat#: X23-11-ZQ146) Sialyl-Lc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ162) Lewis a Cer (d18:1/16:0) (Cat#: X23-11-ZQ175) nLc4Cer (d18:1/18:0) (Cat#: X23-11-ZQ190)
Cyclodextrin
Methyl-γ-cyclodextrin (DS 12) (Cat#: X23-11-YM119) Carboxymethyl-ɑ-cyclodextrin sodium salt (Cat#: X23-11-B003) Carboxymethyl-γ-cyclodextrin sodium salt (Cat#: X23-11-B004) Succinyl-ɑ-cyclodextrin (Cat#: X23-11-B005) Succinyl-γ-cyclodextrin (Cat#: X23-11-B006) ɑ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B007) β-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B008) γ-Cyclodextrin sulfate sodium salt (Cat#: X23-11-B009)
Dextran
Lysine-dextran, MW 4 kDa (Cat#: X22-09-ZQ273) Phenyl-dextran, MW 150 kDa (Cat#: X22-09-ZQ279) FITC-Q-dextran, MW 10 kDa (Cat#: X22-09-ZQ280) FITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ283) TRITC-lysine-dextran, MW 10 kDa (Cat#: X22-09-ZQ287) FITC-dextran sulfate, MW 10 kDa (Cat#: X22-09-ZQ291) Dextran amine, MW 20 kDa (Cat#: X22-09-ZQ377) TRITC-dextran, MW 40 kDa (Cat#: X22-09-ZQ383) Biotin-dextran-FITC, MW 20 kDa (Cat#: X22-09-ZQ389)
Online Inquiry

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Important Links

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0